2017 has been an active year for AXIM Biotech (OTCQX: AXIM), with a new services agreement and patent filing updates. AXIM entered into a new services agreement with a contract research organization in Israel, focusing on a clinical proof-of-concept study of its Gabapentin and cannabidiol chewing gum product line. The study will test the effectiveness of this product in the treatment of restless leg syndrome.
About Restless Leg Syndrome
Restless leg syndrome, sometimes known as Willis-Ekbom Disease, is a persistent condition that causes irritating sensations in the legs. Sufferers of this syndrome have the unpleasant urge to move their legs, often during the night when they are trying to sleep. The condition often worsens during long periods of inactivity, having a significant effect on the sufferer’s ability to get adequate rest. It is believed that the cause of restless leg syndrome is in the brain, and it can lead to a significant increase in rates of exhaustion, depression and anxiety. According to researchers, as many as 10 percent of Americans may suffer from restless leg syndrome, and the onset of the condition can occur at any age.
Cannabidiol as a Treatment for Restless Leg Syndrome
Treatment options for those suffering from restless leg syndrome have historically been limited. AXIM CEO Dr. George E. Anastassov explained his hopes that the double-blind study will yield positive indications for AXIM’s chewing gum product in the treatment of this troubling syndrome. Israel is at the cutting edge of cannabinoid research, so the agreement between this organization and AXIM holds significant promise.
The study will include a single-center phase 2 trial conducted by the CRO in Israel. The approximately 30 patients who have agreed to participate in the study will be given AXIM’s CBD and Gabapentin chewing gum to help treat their RLS symptoms. Both pre- and clinical proof-of-concept studies will be conducted in order to determine the effectiveness of the product for this specific treatment indication. AXIM’s CBD chewing gum, known as the CanChew and CanChew+ product lines, are currently in clinical trials for the treatment of IBS as well. MedChew Rx gum is being tested for effectiveness in the treatment of multiple sclerosis symptoms, such as spasticity and pain.
AXIM and the Opioid Epidemic
The opioid epidemic is a global health crisis that is estimated to affect more than 12.5 million people who misuse prescription opioids in the United States alone. Only two million have received a formal opioid addiction diagnosis in the United States, but such addiction results in more than 33,000 deaths and costs billions in damages each year. Nonetheless, irresponsible opioid prescribing practices continue to contribute to this fatal issue. One of the major factors in the opioid addiction epidemic is the lack of education about non-addictive pain treatment options.
Recently, AXIM Biotechnologies announced a patent on its controlled-release CBD chewing gum in the treatment of opioid addiction. The chewing gum may also be helpful when used as a treatment alternative to opioids for chronic pain. Most people become addicted to opioids after first obtaining a legal prescription for the treatment of pain after an accident or another related medical condition. CBD products could be used to treat pain without the risk of addiction that is associated with opioid-based treatment regimens. Opioid addiction therapy using CBD gum involves replacement therapy, in which a non-addictive substance is used in place of the addictive substance to treat pain.
Research supports the theory that cannabinoids, specifically cannabidiol products, can help decrease overpowering cravings for opioids and other narcotics. These cravings are one of the main reasons why opioid addicts have such a difficult time recovering over the long term. Because AXIM’s CBD chewing gum product line is easily metabolized and does not come with the health risks associated with opioids, it is a viable alternative for those suffering from chronic pain and other debilitating conditions. Cannabinoids may also be used in conjunction with opioid treatments to reduce the dosage of opioids the patient needs to take in order to treat pain, thus reducing the risk of opioid addiction.
In addition to the biochemical properties of cannabinoids, research shows that chewing is a stress-reducing action that can be used to improve oral health and increase the release of hormones such as serotonin and dopamine. Many people self-medicate chemical imbalances in these hormones by abusing narcotics. Chewing gum not only improves the bioavailability of cannabinoids, but it provides patients with a healthy alternative habit to indulge that may make overcoming opioid addiction easier.
As the CanChew, CanChew+ and MedChew Rx product lines move forward in clinical trials and development, patients suffering from multiple sclerosis, opioid addiction, restless leg syndrome, and other chronic conditions will have more treatment options to choose from. As the opioid epidemic continues to worsen, the development of non-addictive treatment alternatives is more crucial than ever before.
About the Author
Stuart Smith is the CEO and Founder of SmallCapVoice.com. SmallCapVoice.com. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://smallcapvoice.com/blog/the-small-cap-daily-small-cap-newsletter/